XML 22 R13.htm IDEA: XBRL DOCUMENT v3.22.2
Financial Royalty Assets
 6 Months Ended
Jun. 30, 2022
Receivables [Abstract]  
Financial Royalty Assets Financial Royalty Assets
Financial royalty assets consist of contractual rights to cash flows relating to royalty payments derived from the expected sales of patent-protected biopharmaceutical products that entitle us and our subsidiaries to receive a portion of income from the sale of such products by third parties.

The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets as of June 30, 2022 and December 31, 2021 are as follows (in thousands):
As of June 30, 2022
Estimated Royalty Duration (1)
Gross Carrying ValueCumulative Allowance for Changes in Expected Cash Flows (Note 6)
Net Carrying Value (5)
Cystic fibrosis franchise
2037 (2)
$5,347,911 $(54,609)$5,293,302 
Tysabri
(3)
1,759,427 — 1,759,427 
Imbruvica2027-20321,439,443 (417,165)1,022,278 
Xtandi2027-20281,053,621 (153,154)900,467 
Tremfya2031-2032876,834 — 876,834 
Evrysdi
2030-2035 (4)
746,524 (1,992)744,532 
Other2020-20404,824,393 (1,110,515)3,713,878 
Total$16,048,153 $(1,737,435)$14,310,718 
Less: Cumulative allowance for credit losses (Note 6)(247,845)
Total financial royalty assets, net$14,062,873 
(1)Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.
(2)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.
(3)RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
(4)Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion.
(5)The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.

As of December 31, 2021
Estimated Royalty Duration (1)
Gross Carrying ValueCumulative Allowance for Changes in Expected Cash Flows (Note 6)
Net Carrying Value (5)
Cystic fibrosis franchise
2037 (2)
$5,335,641 $(48,636)$5,287,005 
Tysabri
(3)
1,846,069 (16,617)1,829,452 
Imbruvica2027-20321,438,730 (236,871)1,201,859 
Xtandi2027-20281,100,065 (172,101)927,964 
Tremfya2031-2032881,671 — 881,671 
Evrysdi
2030-2035 (4)
727,774 — 727,774 
Other2020-20404,697,591 (909,916)3,787,675 
Total$16,027,541 $(1,384,141)$14,643,400 
Less: Cumulative allowance for credit losses (Note 6)(310,804)
Total financial royalty assets, net$14,332,596 
(1)Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.
(2)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.
(3)RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
(4)Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion.
(5)The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.